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During their second pregnancy with diagnosed
HIV (nU 1177), two-fifths of women in the
UK/Ireland not on antiretroviral therapy (ART)
at conception had an immunological indication
for treatment (CD4R <350 cells/ml), of whom
nearly half had CD4R at least 350 cells/ml in their
previous pregnancy. Those initiating ART during
pregnancy had a 4.3-fold increased odds of detect-
able viral load at delivery compared with those
conceiving on treatment, suggesting that continu-
ation of ARTafter pregnancy may be beneficial for
many women.
HIV-positive pregnant women not requiring treatment
for their own health may take short-course antiretroviral
therapy (ART) to prevent vertical transmission [1,2].
Although this is an effective prevention measure [3–5],
increased morbidity and mortality among people
randomized to scheduled HIV treatment interruptions
have been reported in non-pregnant populations [6,7],
which may have implications for optimal management of
HIV in childbearing women. WHO guidelines provide
the option of lifelong ART for pregnant women,
irrespective of health status (‘option Bþ’) [8,9].
Pregnancy incidence among HIV-positive women in
the UK is increasing [10], partly driven by the growing
number of women having repeat pregnancies [11].
National surveillance data on diagnosed HIV-positive
women reported with more than one pregnancy provide
the opportunity to investigate immunological status at the
start of second pregnancy, and viral suppression by
delivery, in women not on ARTat conception. This helps
address the question of whether lifelong ART might be
beneficial for all pregnant women.
In the UK/Ireland, pregnancies in diagnosed HIV-
positive women are reported to the National Study of
HIV in Pregnancy and Childhood (NSHPC) as described
elsewhere [12]. We analysed data on repeat pregnancies
(second reported since HIV diagnosis) during 2000–2010
in women not on ART at conception (53% of second
pregnancies). First antenatal CD4þ cell counts, prior to
ART initiation, were used. UK national guidelines
have recommended a treatment threshold of less thanCopyright © Lippincott Williams & Wilkins. Unaut
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detectable maternal viral load at delivery (50 copies/ml),
the comparison group comprised second pregnancies
(resulting in live/stillbirth) to women conceiving on ART.
Multivariable analyses were conducted using forward-
fitted logistic regression models in STATA 12.0 (StataCorp,
College Station, Texas, USA).
The main study group consisted of 1177 pregnancies to
women not on treatment at conception; 1063 resulted in
a live or stillbirth. Most (76.0%) were in women from
sub-Saharan Africa, median age was 30.3 years [inter-
quartile range (IQR) 26.9–33.8], and 43.4% occurred
during 2008–2010. Median interval between concep-
tion of first and second pregnancies was 2.3 years (IQR
2.2–2.5).
Median pre-ART antenatal CD4þ cell count at second
pregnancy (available for 838/1177) was 390 cells/ml
(IQR 271–534), measured at median 15.0 gestational
weeks (IQR 9.6–20.6). Pregnancies in earlier years were
more likely to have missing baseline CD4þ cell counts
(test for trend: P< 0.001), but there was no significant
difference for other demographics (maternal age, world
region of origin, probable source of HIV infection, or
inter-pregnancy interval). Overall, 40.6% (340/838) of
women not on ART at conception had reached the
immunological threshold for treatment (39.8% during
2008–2010); 10% (n¼ 85) were severely immunosup-
pressed (<200 cells/ml). Half of those not yet requiring
treatment for their own health (245/498) had CD4þ
350–499 cells/ml. Among women requiring treatment
for their own health at their second pregnancy, 44.3%
(93/210) had CD4þ at least 350 cells/ml at their first
pregnancy; note also that 25.9% (93/359) with CD4þ at
least 350 cells/ml at first pregnancy had CD4þ below
350 cells/ml by their second pregnancy.
Among 1063 women having a live/stillbirth, most
(n¼ 1028) received antenatal ART, starting at median
23.7 gestational weeks (IQR 20.4–27.0), with earlier
initiation over calendar time; from 25.6 weeks (IQR
23.4–29.5, 2000–2002) to 21.5 (IQR 18.6–24.5, 2009–
2010) (test for trend: P< 0.001). Analyses of detectable
viral load at delivery were conducted on these 1028
women, and 914 women conceiving on ART. The
former were younger, more likely to have delivered
during an earlier time period, and to have received
protease inhibitor-based highly active antiretroviral
therapy during pregnancy (all P< 0.05). Delivery viral
loads were reported for similar proportions in both
groups: 59.6% and 54.2%, respectively. Imputation ofhorized reproduction of this article is prohibited.
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an undetectable viral load earlier in pregnancy increased
data to 86.8% (1686/1942) for all pregnancies: 81.7%
among those not on ART at conception and 92.6%
among those who were. Overall, 16.2% (273/1686)
had detectable viral load (median 188 copies/ml, IQR
90–590, range 51–412 000) – 26.2% in women starting
ART in pregnancy and 6.3% among those conceiving on
ART (Table 1). Vertical transmission rates were 0.91%
(8/878) and 0.27% (2/740), respectively (P¼ 0.121).
Among those starting ART during pregnancy, the
proportion not suppressing by delivery increased the
later ART was started, from 15.8% (6/38) in the first to
35.7% (71/199) in the third trimester.
In multivariable analyses, women starting ART during
pregnancy had 4.3-fold increased odds of detectable viral
load adjusting for time period, region, ART type,
and earliest CD4þ cell count, compared with womenpyright © Lippincott Williams & Wilkins. Unautho
Table 1. Univariable and multivariable analyses of the association between
second pregnancies to diagnosed HIV-positive women.
Detectable/total (%)
Univ
OR
Timing of ART
After conception 220/840 (26.2) 5.31 (3
Prior to conception 53/846 (6.3) 1
Maternal age group (years)
<25 33/184 (17.9) 1
25–34 183/1049 (17.4) 0.97 (0
35 57/452 (12.6) 0.66 (0
Maternal region of origin
UK/Ireland 30/234 (12.8) 1
Sub-Saharan Africa 218/1317 (16.6) 1.35 (0
Elsewhere 24/134 (17.9) 1.48 (0
Maternal HIV risk factor
Othera 260/1612 (16.1) 1
Injecting drug use 7/34 (20.6) 1.35 (0
Time period
2000–2002 12/47 (25.5) 2.34 (1
2003–2005 76/338 (22.5) 1.98 (1
2006–2008 110/715 (15.4) 1.24 (0
2009–2010 75/586 (12.8) 1
Reporting region
London 141/830 (17.0) 1
Elsewhere in England 116/647 (17.9) 1.07 (0
Wales/Scotland/N Ireland 3/63 (4.8) 0.24 (0
Ireland 13/145 (9.0) 0.48 (0
Type of antenatal ART
Mono/dual 33/71 (46.5) 3.96 (2
HAART – PI-based 177/985 (18.0) 1
HAART – NNRTI-based 45/536 (8.4) 0.41 (0
HAART – otherb 18/94 (19.1) 1.13 (0
Earliest CD4þ cell countc (cells/ml)
500 60/534 (11.2) 1
350–499 82/486 (16.9) 1.60 (1
200–349 77/442 (17.4) 1.67 (1
<200 38/128 (29.7) 3.34 (2
aOR, adjusted odds ratio; ART, antiretroviral therapy; CI, confidence interval
reverse-transcriptase inhibitor; NRTI, nucleoside reverse-transcriptase inhi
aIncludes heterosexual transmission, originating from a high HIV prevalen
bIncludes those receiving NNRTIs and PIs, and those receiving NRTIs only
cEarliest measurement in women’s second reported pregnancy, not restricconceiving on ART (Table 1). Earliest viral load was not
included in the model as most women conceiving on
ART had undetectable viral load. As a sensitivity analysis,
the model was re-run using the original non-imputed
viral load variable; the adjusted odds ratio (aOR) was
similar [3.85, 95% confidence interval (CI) 2.65–5.59].
The association was also similar when the main model was
re-run excluding seven ‘high-risk’ women who received
less than 14 days ART (aOR 4.31, 95% CI 3.01–6.18).
Our results should be interpreted in the light of some
international guidelines now recommending ART
initiation regardless of CD4þ cell count [15,16], and
the debate around potential benefits and risks of option
Bþ [17]. Here, two-fifths of women not on ART at
conception of their second pregnancy had an immuno-
logical indication for treatment according to current UK
guidelines [13,14]. For some, this may reflect disengage-
ment from HIV care postnatally, which needs addressing,rized reproduction of this article is prohibited.
timing of ART and detectable maternal viral load at delivery among
ariable analyses Multivariable analysis
(n¼1590)
95% CI P-value aOR 95% CI P-value
.86–7.30) 4.34 (3.03–6.20)
<0.001 1 <0.001
0.046
.64–1.46)
.41–1.05)
0.288
.90–2.03)
.83–2.66)
0.499
.58–3.13)
.16–4.70) <0.001 3.32 (1.38–8.00)
.39–2.81) 1.90 (1.24–2.90)
.90–1.70) 1.05 (0.74–1.49)
1 0.002
0.001 1 <0.001
.81–1.40) 1.34 (0.98–1.83)
.08–0.79) 0.31 (0.09–1.06)
.26–0.88) 0.42 (0.22–0.80)
.42–6.50) <0.001 2.89 (1.65–5.06)
1 <0.001
.29–0.58) 0.48 (0.32–0.74)
.66–1.91) 1.16 (0.62–2.18)
<0.001 1 <0.001
.12–2.29) 1.94 (1.31–2.87)
.16–2.40) 2.00 (1.34–2.97)
.10–5.31) 4.50 (2.69–7.51)
; HAART, highly active antiretroviral therapy; NNRTI, non-nucleoside
bitor; OR, odds ratio; PI, protease inhibitor.
ce area, and vertical transmission.
– groups combined due to small numbers.
ted to measurements taken prior to ART initiation.
Research Letter 1371particularly for women initiating ART late in their
subsequent pregnancy. Possible barriers to access include
stigma, fear of disclosure, and childcare responsibilities
[18–20]. It is also salient that a quarter of women with
CD4þ at least 350 cells/ml at their first pregnancy had
fallen below the treatment threshold by their second
pregnancy. Significant levels of disease progression after
discontinuation of antenatal ART have been reported
elsewhere [21–24]. Longer duration of antenatal ART
decreases risk of detectable viral load at delivery, and
hence the risk of vertical transmission [4,5,25–27], but
the four-fold increased odds of detectable virus among
those initiating ART during, rather than before, preg-
nancy is striking.
In conclusion, these findings suggest that in terms of
maternal health and vertical transmission, continuation of
ART post-natally could have benefits for many HIV-
positive women and their future pregnancy outcomes.
However, this needs consideration in the broader context
of issues such as potential toxicity (particularly first-
trimester ART exposure), adherence, drug resistance,
obstetric outcomes, and women’s views and preferences.Acknowledgements
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